Compare Ascendis Pharma A/S (ASND) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs KraneShares CSI China Internet ETF — how do they compare? Ascendis Pharma A/S trades at $263.68 (market cap $17.74B), while KraneShares CSI China Internet ETF trades at $26.23. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.
| ASND | KWEB | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $42.94 |
52-Week Low | $163.32 | $23.63 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
KWEB trades at $26.38, down 0.38% on the day, with technical indicators showing mixed signals - bullish moving averages but neutral oscillators. The ETF offers concentrated exposure to Chinese internet and AI companies, currently trading near 52-week lows according to Seeking Alpha analysis from June 29, 2026. Recent news highlights China's significant AI infrastructure investments and strong export performance, providing potential catalysts for the underlying holdings.
The ETF presents a value opportunity with Chinese tech stocks trading at discounts to Western peers, though geopolitical tensions and regulatory risks remain concerns. AI-driven growth and government support for technology sectors offer upside potential, but investors face China-specific market volatility and US-China trade friction risks that could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →
